VAERS reports by lot

Pfizer COVID-19 lot FP7139: VAERS reports

335 VAERS reports list lot FP7139 as a Pfizer COVID-19 vaccine, received between 2022-06-23 and 2024-06-11. Data: VAERS public files through 31 December 2024 (site extract 2026-07-04).

Read this first. VAERS accepts reports from anyone, and a report does not establish that the vaccine caused the event. A lot's report count mostly reflects how many doses it contained, when it was used and who received it; no administered-dose counts are published for this lot, so counts are not rates and cannot rank lots against each other. Lot numbers in VAERS reports are typed by reporters and are sometimes wrong.
335
Reports
18%
Marked serious
2
With a death outcome
20
Months with reports

Symptom categories in these reports

A report can mention several categories, so the counts add up to more than the number of reports.

CategoryCount%
General / Systemic (non-local)12320%
Neurological9616%
Cardiac / Cardiovascular9616%
Respiratory7112%
Gastrointestinal6911%
Dermatological (non-injection-site)346%
Injection-site / Local reaction346%
Allergic / Anaphylactic274%
Thrombotic / Hematological213%
Musculoskeletal213%
Psychiatric / Neuropsychiatric122%
Autoimmune / Immune-mediated71%
Reproductive / Menstrual20%

Where reports came from

U.S. state of the reporter, where given (top 12).

California30
Michigan23
Colorado14
New York13
Texas12
Wisconsin12
Florida11
Pennsylvania10
North Carolina8
New Jersey8
Washington8
Missouri6

Reports by month received

2022-063
2022-0757
2022-0880
2022-0945
2022-1028
2022-1111
2022-128
2023-0114
2023-025
2023-034
2023-046
2023-054
2023-0614
2023-0712
2023-0838
2023-112
2023-121
2024-021
2024-031
2024-061

Products recorded with this lot

Manufacturer and product as reported in VAERS. Reports listing the lot under more than one product are counted once.

Related

Source: VAERS public data (CDC/FDA), grouped by manufacturer and lot by the Open Source Medicine Foundation; extract 2026-07-04 16:35 UTC. Not medical advice. Report errors via contact.